Get All Access for FREEMarket News & Research,
Live Transcripts & Audio,
and a whole lot more…
$SIAL 1Q15 10-Q: Effective tax rate for the three months ended March 31, 2015 increased to 28% vs. 27.2% for the same period of 2014. The increase in the effective tax rate is primarily attributable to increases in uncertain tax positions which were partially offset by lower tax rates in certain foreign jurisdictions.
For full-year 2018, $WHR expects GAAP diluted EPS of $12.45-13.45 and ongoing diluted EPS of $14.50-15.50. The company expects to generate cash from operating activities of approx. $1.7-1.8Bil and free cash flow of approx. $1-1.1Bil for FY18.
$WHR reported a net loss of $268MM or $3.69 per share in 4Q17 compared to a net income of $180MM or $2.36 per share in 4Q16. This includes a one-time non-cash charge of approx. $420MM related to tax reform. 4Q17 ongoing diluted EPS was $4.10. Net sales were $5.7Bil, up 1% compared to the prior-year period.
The BoD of $AOS approved a 29% increase in its quarterly cash dividend to $0.18 per share. This is consistent with the 5-year compound annual growth rate of its dividend which is over 25%. The dividend is payable on Feb. 15, 2018, to shareholders of record Jan. 31, 2018.
$ACET's finished dosage form generics subsidiary Rising Pharmaceuticals launched the first generic for Efavirenz Capsules. This is an FDA-approved generic version of the reference listed drug, Sustiva from $BMY, which in combination with other drugs is indicated for the treatment of HIV-1 infection in adults and pediatric patients.
$RBC said Charles Hinrichs, VP and CFO, will retire on March 31, 2018. Hinrichs has served as Regal's CFO since September 2010. The BoD appointed Robert Rehard as the new VP and CFO, effective April 1, 2018. Rehard joined Regal in January 2015 as VP, Corporate Controller and Principal Accounting Officer.
For full-year 2017, $WHR expects GAAP EPS of $11.10-11.40 and ongoing EPS of $13.60-13.90. The company expects to generate cash from operating activities of $1.55-1.6Bil and free cash flow of approx. $900MM. Capital spending is expected to be $650-700MM for 2017.
$WHR reported net income of $276MM or $3.72 per share in 3Q17 compared to $238MM or $3.10 per share in 3Q16. GAAP net earnings were positively impacted by lower income tax expense of approx. $65MM during 3Q17. Ongoing EPS was $3.83 in 3Q17. Net sales were $5.4Bil, an increase of more than 3% versus last year.
$WST, a pharmaceutical services firm, said a recent study showed its injection guide ID Adaptor could be used for administering intradermal injections in a safe and effective manner. The clinical trial evaluated the feasibility of conducting a door-to-door vaccination campaign to administer Fractional Inactivated Poliovirus Vaccine to children.